Genomatica awarded $765,000 Phase II SBIR grant from NIH.
"We are excited to receive this Phase II continuation award from the NIH who maintain their support for modeling and simulation technologies," said Christophe Schilling, Ph.D., Chief Technology Officer of Genomatica and Principal Investigator for the grant. "In the Phase I effort, Genomatica successfully demonstrated the use of its models of cellular metabolism to predict gene expression patterns in yeast, an important research organism. The Phase II effort will further illustrate the power of systems biology and the use of computational metabolic models for the visualization, analysis and integration of gene expression data. Most importantly, this program will yield product and technology enhancements that will have an immediate and broad positive impact for our clients across the academic, industrial and medical biotechnology communities."
The NIH SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative technologies and methodologies that have the potential for commercialization and public benefit.
|Printer friendly Cite/link Email Feedback|
|Publication:||EDP Weekly's IT Monitor|
|Article Type:||Brief Article|
|Date:||Nov 10, 2003|
|Previous Article:||FAA keeps U.S. flying with prognosis from integrated research.|
|Next Article:||SatCon receives $1M award for development of photovoltaic inverter.|